Natco Pharma Share Price in Focus; To Increase Investment In eGenesis to $16.70 Million

Natco Pharma has increased the amount it plans to invest in eGenesis, a U.S.-based biotechnology company working on gene-edited organ transplantation. The proposed investment has been raised to $16.70 million from the earlier disclosed $14 million. 

The fresh investment will be made through Natco's wholly owned subsidiaries and will take the company's total investment in eGenesis to $24.70 million after completion. 

Investment to Come Through Two Subsidiaries 

Natco Pharma (Canada) Inc. will invest $13.70 million, while Natco Pharma USA LLC will put in another $3 million. 

The money will be invested through convertible promissory notes carrying an interest rate of 8% compounded annually. Natco said no additional shares will be acquired at the time the investment is completed. 

Natco's Earlier Investment in eGenesis 

Natco had invested $8 million in eGenesis in 2024 through NATCO Pharma (Canada) Inc. The latest investment will add another $16.70 million to its exposure to the biotechnology company. 

The proposed transaction is expected to be completed by October 31, 2026. 

eGenesis Works on Transplantable Organs 

eGenesis is developing gene-editing technology aimed at producing organs from pigs for transplantation into humans. Its work focuses on addressing biological barriers that can cause the human body to reject organs from another species. 

The company is currently working on programmes involving kidney transplantation, acute liver failure and heart transplantation. 

Progress in Porcine Kidney Transplants 

In March 2024, eGenesis announced the first porcine kidney transplant in a living patient. The company later carried out transplants in two additional patients. 

Natco's release said the outcomes from these procedures were exceptionally positive. 

Investment Targets New Therapeutic Programmes 

Natco said the investment is aimed at supporting new-age therapeutic programmes addressing critical unmet medical needs. 

eGenesis is a clinical-stage, pre-revenue biotechnology company incorporated in 2015 and based in the United States. 

Read More: Linde India Share Price in Focus; Secures Land Parcel in Sanand for Semiconductor Packaging Gas Facility! 

Natco Pharma Share Price Performance  

As of 29 September 2026, at 10:58 AM, Natco Pharma Ltd share price is trading at ₹839 per share, reflecting a surge of 1.26% from the previous trading session. 

Conclusion 

The increased investment takes Natco Pharma's total investment in eGenesis to $24.70 million. The funding will support the biotechnology company's ongoing work in gene editing and organ transplantation programmes. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.